Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street to higher close as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
| (NASDAQ: PCVX) | Delayed: 63.23 -3 (4.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.23 | 52 Week High | $ | |||
| Open | $66.02 | 52 Week Low | $ | |||
| Day High | $67.47 | P/E | N/A | |||
| Day Low | $63.09 | EPS | $ | |||
| Volume | 3,272,122 | |||||
